Below are the most recent publications written about "Nucleocapsid Proteins" by people in Profiles.
-
Lin AE, Diehl WE, Cai Y, Finch CL, Akusobi C, Kirchdoerfer RN, Bollinger L, Schaffner SF, Brown EA, Saphire EO, Andersen KG, Kuhn JH, Luban J, Sabeti PC. Reporter Assays for Ebola Virus Nucleoprotein Oligomerization, Virion-Like Particle Budding, and Minigenome Activity Reveal the Importance of Nucleoprotein Amino Acid Position 111. Viruses. 2020 01 15; 12(1).
-
Biswas S, Willis LG, Fang M, Nie Y, Theilmann DA. Autographa californica Nucleopolyhedrovirus AC141 (Exon0), a Potential E3 Ubiquitin Ligase, Interacts with Viral Ubiquitin and AC66 To Facilitate Nucleocapsid Egress. J Virol. 2018 02 01; 92(3).
-
Jegaskanda S, Co MDT, Cruz J, Subbarao K, Ennis FA, Terajima M. Induction of H7N9-Cross-Reactive Antibody-Dependent Cellular Cytotoxicity Antibodies by Human Seasonal Influenza A Viruses that are Directed Toward the Nucleoprotein. J Infect Dis. 2017 03 01; 215(5):818-823.
-
Battisti AJ, Meng G, Winkler DC, McGinnes LW, Plevka P, Steven AC, Morrison TG, Rossmann MG. Structure and assembly of a paramyxovirus matrix protein. Proc Natl Acad Sci U S A. 2012 Aug 28; 109(35):13996-4000.
-
McGinnes LW, Pantua H, Laliberte JP, Gravel KA, Jain S, Morrison TG. Assembly and biological and immunological properties of Newcastle disease virus-like particles. J Virol. 2010 May; 84(9):4513-23.
-
Co MD, Orphin L, Cruz J, Pazoles P, Green KM, Potts J, Leporati AM, Babon JA, Evans JE, Ennis FA, Terajima M. In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responses. Vaccine. 2009 Jan 07; 27(2):319-27.
-
Fang M, Nie Y, Dai X, Theilmann DA. Identification of AcMNPV EXON0 (ac141) domains required for efficient production of budded virus, dimerization and association with BV/ODV-C42 and FP25. Virology. 2008 May 25; 375(1):265-76.
-
Powell TJ, Strutt T, Reome J, Hollenbaugh JA, Roberts AD, Woodland DL, Swain SL, Dutton RW. Priming with cold-adapted influenza A does not prevent infection but elicits long-lived protection against supralethal challenge with heterosubtypic virus. J Immunol. 2007 Jan 15; 178(2):1030-8.
-
Leung DT, van Maren WW, Chan FK, Chan WS, Lo AW, Ma CH, Tam FC, To KF, Chan PK, Sung JJ, Lim PL. Extremely low exposure of a community to severe acute respiratory syndrome coronavirus: false seropositivity due to use of bacterially derived antigens. J Virol. 2006 Sep; 80(18):8920-8.
-
Prabu-Jeyabalan M, Nalivaika EA, Romano K, Schiffer CA. Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate. J Virol. 2006 Apr; 80(7):3607-16.